CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A
22 September 2021 - 3:00PM
CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B
PAM as Potential Treatment for CMT1A
Ad Hoc Announcement Pursuant to
Art. 53 LR
Glenolden, PA and
Geneva, Switzerland,
September 22, 2021 (GLOBE
NEWSWIRE) - The Charcot–Marie–Tooth
Association (CMTA), the largest philanthropic funder of CMT
research worldwide, and Addex Therapeutics (SIX: ADXN and Nasdaq:
ADXN), a clinical-stage pharmaceutical company pioneering
allosteric modulation-based drug discovery and development, today
announced a collaboration to investigate a potential therapy for
CMT type 1A (CMT1A), the most common subtype of the disease, which
affects approximately 1.5 million people.
The primary goal of the collaboration is to
evaluate the benefit of Addex’s proprietary positive allosteric
modulator’s (PAM’s) targeting the gamma-aminobutyric acid subtype B
(GABAB) receptor in rodent models of CMT1A. The GABAB receptor has
previously been shown to be instrumental in controlling the
overexpression of Peripheral Myelin Protein-22 (PMP22) in a rat
model of CMT1A. Elevated PMP22 is closely associated with the
disabling peripheral neuropathy that accompanies CMT1A.
The CMTA’s Strategy to Accelerate Research
(STAR) connects leading CMT clinicians and researchers with
pharmaceutical partners committed to developing treatments and a
cure for CMT. Strategic alliances with pharmaceutical partners like
Addex Therapeutics support drug development efforts to deliver
therapies to CMT patients.
“We are excited to establish this partnership
with Addex Therapeutics as they work to advance their PAM’s to
treat CMT1A,” said CMTA’s CEO Amy Gray. “Strategic research
partnerships with companies like Addex is a central part of our
strategy to accelerate the development of treatments for the CMT
community. Since launching STAR 12 years ago, the CMTA has been
able to establish research partnerships with almost 40
pharmaceutical and biotech companies, and leading research labs
around the world. We share Addex’s enthusiasm and passion for
developing life-changing treatments for patients.”
The research alliance with Addex will include
joint study planning aimed at the chronic dosing of select GABAB
PAM’s in rodent models of CMT1A, followed by detailed assessments
aimed at measuring the improvement of key outcomes. These outcome
measures include biomarkers, motor function, electrophysiology and
peripheral nerve histology. This is made possible through the
CMTA’s preclinical testing alliance:
www.cmtausa.org/our-research/for-researchers/cmta-preclinical-testing-network/
“By combining the expertise of both the
Charcot-Marie Tooth Association with our proven track record in the
discovery and development of allosteric modulators, we aim to
further understand how targeting GABAB with a positive allosteric
modulator could benefit patients with CMT1A,” said Tim Dyer, CEO of
Addex Therapeutics. “As we move towards IND enabling studies, we
look forward to working with the CMTA to build scientific evidence
supporting our approach to tackle this tremendous unmet need.”
About CMTA
The CMTA is the largest philanthropic funder of
CMT research worldwide. The CMTA’s Strategy to Accelerate Research
(STAR) brings the best CMT researchers, clinicians and experts in
therapy development together with pharmaceutical and biotechnology
companies and patients to expedite the development of treatments
for CMT. The CMTA is also actively working to help improve the
quality of life for all families living with CMT by offering
educational programs and materials, hosting patient and
professional conferences, providing support to families through its
nationwide branch system through North America and more. More
information can be found at www.cmtausa.org.
About Addex
Therapeutics:
Addex Therapeutics is a clinical-stage
pharmaceutical company focused on the development and
commercialization of an emerging class of novel orally available
small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is in a pivotal registration
clinical trial for Parkinson’s disease levodopa induced dyskinesia
(PD-LID). Addex is also investigating dipraglurant's therapeutic
use in blepharospasm (a type of dystonia), for which a clinical
trial is expected to be initiated in Q3 2021. Addex's third
clinical program, ADX71149 (mGlu2 positive allosteric modulator or
PAM), developed in collaboration with Janssen Pharmaceuticals,
Inc., is in a Phase 2a proof of concept clinical trial for the
treatment of epilepsy. Indivior PLC has licensed Addex’s
GABAB PAM program for the development of drug candidates with
a focus in addiction. Preclinical programs ongoing with Addex
include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for
mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease
and mGlu3 PAM for neurodegenerative disorders. Addex shares are
listed on the SIX Swiss Exchange and American Depositary Shares
representing its shares are listed on the NASDAQ Capital Market,
and trade under the ticker symbol "ADXN" on each exchange.
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55 PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
James
CarbonaraHayden IR(646)-755-7412james@haydenir.com |
Addex Forward Looking
Statements:
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including in respect of the
anticipated initiation of clinical trials. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in the Company’s Annual Report on Form 20-F filed with
the SEC on March 11, 2021, as well as market conditions and
regulatory review.
Any forward-looking statements contained in this
press release represent Addex Therapeutics’ views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Addex Therapeutics explicitly disclaims
any obligation to update any forward-looking statements.
Addex Therapeutics (LSE:0QNV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Addex Therapeutics (LSE:0QNV)
Historical Stock Chart
From Apr 2023 to Apr 2024